3 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies (PACE)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of limited treatment options and poor outcome by applying a novel, off-the-shelf allogeneic placenta-derived stromal cell product (PLX-PAD). Despite improvements in medical care and revascularization, patients with CLI continue to have a high risk of major amputat ...
Voir le projet
9
Participants partenaires
TERMINÉ
Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics (3D NEONET)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of age, a growing demographic group in EU. More than 8 million people lose their lives to cancer every year, making cancer a leading cause of pre-mature mortality in the world. The main hallmarks of severe eye conditions (i.e angiogenesis, inflammation and vascul ...
Voir le projet
18
Participants partenaires
TERMINÉ
Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients (MIROCALS)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
Amyotrophic Lateral Sclerosis (ALS) is a fatal degenerative disorder of the brain and spinal cord affecting some 40,000 individuals in Europe, causing 11,000 deaths each year. Our pioneering work on riluzole showed that it is possible to modify ALS progression but all subsequent trials of potential neuroprotective agents have failed. Thus, drug development in ALS, including trial design, patient s ...
Voir le projet